Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
BOULDER, Colo. (AP) _ Array BioPharma Inc. (ARRY) on Tuesday reported a loss of $34.1 million in its fiscal second quarter. The Boulder, Colorado-based company said it had a loss of 17 cents per share ...
Andrew Peters - UBS Good morning and welcome everyone to the second day of the 2012 UBS Global Life Sciences conference. My name is Andrew Peters and I’m a member of the biotech research team here at ...
The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product, ...
Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...
Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...
Shares are trading flat year to date and the stock remains solidly in value territory, even in the absence of near-term drivers. Clinical trial collaborations with Merck and Bristol-Myers Squibb bode ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: ...
* Array Biopharma Inc - FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - FDA set a target action ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results